Genital Psoriasis, Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q)
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
The results of this study are not yet available.
Your participation could last up to 16 months and include 15 visits to the study center
Here you can find out a bit more about the requirements for volunteers who took part in this study
Particpant must have a diagnosis of chronic plaque psoriasis for at least 6 months before entering the study
Participant must have moderate-to-severe psoriasis in the genital area at the time of entering the study
Participant must also have plaque psoriasis in a non-genital area at the time of entering the study
Participant must have failed to respond to, or are intolerant of, at least 1 topical therapy used for treatment of psoriasis affecting the genital area
Participant must agree to use reliable method of birth control, which could include abstinence, during the study and for at least 12 weeks following the last dose of study drug
Participant must not have Pustular, erythrodermic, and/or guttate forms of psoriasis or a history of drug-induced psoriasis
Participant must not have ever received treatment with ixekizumab, secukinumab, brodalumab, or another drug with a similar mode of action
Participant must avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to baseline and during the study
Participant must not currently have cancer or have had cancer within 5 years prior to baseline
Female participants must not be pregnant or breastfeeding